Improving outcomes for patients with Burkitt lymphoma and HIV.

@article{Blinder2008ImprovingOF,
  title={Improving outcomes for patients with Burkitt lymphoma and HIV.},
  author={Victoria Blinder and Amy Chadburn and Richard R. Furman and Susan P. Mathew and John P. Leonard},
  journal={AIDS patient care and STDs},
  year={2008},
  volume={22 3},
  pages={
          175-87
        }
}
  • Victoria Blinder, Amy Chadburn, +2 authors John P. Leonard
  • Published in AIDS patient care and STDs 2008
  • Medicine
  • Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy that occurs with increased frequency among patients infected with HIV. Until recently, the immunocompromised state of patients with HIV and BL was generally deemed to preclude the use of the intensive chemotherapeutic regimens used to treat HIV-negative patients due to toxicity issues. However, the advent of highly active antiretroviral therapy (HAART) and the mounting evidence that less intensive lymphoma regimens are ineffective… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 20 CITATIONS

    Sexually transmitted infections and sexually transmitted diseases

    VIEW 18 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    HIV associated Burkitt's lymphoma.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8).

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 45 REFERENCES

    Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

    Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma.